CoChat
Sign Up
Cited by 73Blood Pressure and Hypertension StudiesDiabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment

von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., Rossing, P.·2015·Diabetic Medicine
DOI 10.1111/dme.12594
Open this paper in CoChat — free account

Abstract

Aims: Glucagon‐like peptide–1 receptor agonist studies have revealed clinically significant reductions in systolic blood pressure (SBP). The aim was to investigate the time course of the anti‐hypertensive effect of liraglutide treatment and potential underlying mechanisms. Methods: We used an open‐label, single‐centre trial; 31 participants with Type 2 diabetes and hypertension completed the study. All participants were treated with liraglutide escalated to a maximum dose of 1.8 mg/day for 7 weeks, followed by a 21–day washout period. The primary outcome was a change in 24–h SBP. Results: Twenty‐four‐h SBP increased by 10 mmHg on day 3 (P = 0.008) and 7 mmHg on day 7 (P = 0.033, 0.6 mg/day). On day 29, (1.8 mg/day), 24–h SBP was 7 mmHg lower compared with baseline (P = 0.11). Following the treatment period (day 49) and after washout (day 70), 24–h BP was equivalent to baseline. In addition, extracellular volume (ECV) was reduced by 2.0 l [95% confidence interval (CI) = 1.0–3.1 l, P < 0.001] and midregional‐pro‐atrial natriuretic peptide (MR–pro ANP) was reduced by 20% (95% CI = 12–28%, P < 0.001). Also, urinary albumin excretion declined by 30% (95% CI = 12–44%, P = 0.003), GFR by 11 ml/min/1.73 m 2 (95% CI = 7.2–14.4 ml/min/1.73 m 2, P < 0.001) and fractional albumin excretion by 29% (95% CI = 3–48%, P = 0.032). Conclusions: Liraglutide treatment was associated with an initial increase in 24–h SBP, followed by a 7 mmHg reduction after escalation to 1.8 mg/day. This effect subsided after 4 weeks of maximum dose. Reductions in ECV and MR–pro ANP may explain the anti‐hypertensive potential. Liraglutide treatment was associated with reversible reductions in albuminuria and GFR, which has to be confirmed in randomized trials.

Integrity signals

Registry

Crossref · 10.1111/dme.12594

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In an uncontrolled study in people with type 2 diabetes, liraglutide initially lowered eGFR, but this result was not confirmed in placebo-controlled studies that assessed measured GFR and kidney hemodynamic function by gold-standard tracer methods.

    “In an uncontrolled study in people with T2D, liraglutide initially lowered eGFR (35), but this result was not confirmed in placebo-controlled studies that assessed mGFR and kidney hemodynamic function by gold-standard tracer methods (36).”

    From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [35]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P.
Affiliations
  • Steno Diabetes Center Gentofte Denmark
  • Aarhus University (DK)
  • University of Copenhagen (DK)
ORCID
Venue
Diabetic Medicine
Publisher
Wiley
Published
2014-10-15
Volume
32
Issue
3
Pages
343-352
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
DOI
10.1111/dme.12594
OpenAlex
W2121198446
Cited by
73
References
7
Citations by year
2026: 1 · 2025: 1 · 2024: 5 · 2023: 8 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 13 · 2016: 9 · 2015: 8
FWCI
6.87
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetic Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
liraglutide, GLP-1 receptor agonists, hypertension, type 2 diabetes, antihypertensive effect, systolic blood pressure, renal effects, extracellular volume, urinary albumin excretion, glomerular filtration rate, dose escalation, washout
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Albuminuria, Antihypertensive Agents, Blood Pressure, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Glomerular Filtration Rate, Heart Rate, Humans, Hypertension, Hypoglycemic Agents, Kidney, Male, Middle Aged, Time Factors, Comorbidity, Incidence, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review